{"id":"NCT00697515","sponsor":"Shire","briefTitle":"Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)","officialTitle":"A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07-18","primaryCompletion":"2008-12-20","completion":"2008-12-20","firstPosted":"2008-06-16","resultsPosted":"2010-02-01","lastUpdate":"2021-06-09"},"enrollment":142,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"LDX","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lisdexamfetamine Dimesylate (LDX, SPD489)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting","primaryOutcome":{"measure":"Permanent Product Measure of Performance (PERMP) Total Score Over the Treatment Day in the Crossover Phase","timeFrame":"2, 4, 8, 10, 12 and 14 hours post-dose on Day 7","effectByArm":[{"arm":"SPD489","deltaMin":312.9,"sd":8.59},{"arm":"Placebo","deltaMin":289.5,"sd":8.59}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["20576091","21566420","21973229","20861583"],"seeAlso":["http://www.fda.gov/opacom/7alerts.html"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":142},"commonTop":["Decreased appetite","Dry mouth","Headache","Insomnia","Upper respiratory tract infection"]}}